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Abstract
Background: Hypospadias is a common inborn error of the male urethral development, for which
the aetiology is still elusive. Polymorphic variants in genes involved in the masculinisation of male
genitalia, such as the androgen receptor, have been associated with some cases of hypospadias. Co-
regulators of the androgen receptor start being acknowledged as possible candidates for hormone-
resistance instances, which could account for hypospadias. One such molecule, the protein
FKBP52, coded by the FKBP4 gene, has an important physiological role in up-regulating androgen
receptor activity, an essential step in the development of the male external genitalia. The presence
of hypospadias in mice lacking fkbp52 encouraged us to study the sequence and the expression of
FKBP4 in boys with isolated hypospadias.
Patients and methods: The expression of FKBP52 in the genital skin of boys with hypospadias
and in healthy controls was tested by immunohistochemistry. Mutation screening in the FKBF4 gene
was performed in ninety-one boys with non syndromic hypospadias. Additionally, two
polymorphisms were typed in a larger cohort.
Results: Immunohistochemistry shows epithelial expression of FKBP52 in the epidermis of the
penile skin. No apparent difference in the FKBP52 expression was detected in healthy controls,
mild or severe hypospadias patients. No sequence variants in the FKBP4 gene have implicated in
hypospadias in our study.
Conclusion: FKBP52 is likely to play a role in growth and development of the male genitalia, since
it is expressed in the genital skin of prepubertal boys; however alterations in the sequence and in
the expression of the FKBP4 gene are not a common cause of non-syndromic hypospadias.
Background
Hypospadias is a common inborn error of the male geni-
tal development, consisting of a midline fusion defect of
the male ventral urethra [1]. The urethral opening is
ectopically located on the ventrum of the penis; and may
be as proximal as the scrotum or perineum. This disorder
occurs in approximately one out of every 300 male live
births worldwide [2]; in Sweden, the incidence is 1.14
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boys per 300 male live births according to the annual
Swedish Malformation Registry. Despite being so com-
mon, its etiology is still largely unknown.
Male sexual differentiation is a process that depends on
androgen action via the androgen receptor (AR). Andro-
gens have a direct role in the fusion of the urethral folds
[3,4]. Variants in the AR gene, such as CAG and GGN
repeat polymorphisms, and in the 5-α reductase 2 gene
(SRD5A2), which converts testosterone (T) to the more
potent dihydrotestosterone (DHT) have been associated
with hypospadias [5,6]. Androgen receptor defects have
been shown to result in varying degrees of impaired mas-
culinisation in XY individuals [7,8]; however this is
thought to be infrequent in hypospadias [9,10]. Other fac-
tors may be more commonly implicated in its complex
aetiology [11], such as environmental endocrine disrupt-
ers, or variants in other genes that are involved in the
endocrine regulation of sexual differentiation.
AR, as a nuclear receptor, is subjected to a complex regu-
lation by co-regulators and general transcription factors,
which modulate androgen-targeted gene expression. In
this context, hormone-resistance syndromes have already
been attributed to disorders of co-regulatory proteins
[12]. In 1999 New et al described two sisters with multiple
partial hormone resistance, in which a co-activator defect
has been proposed as the most likely underlying mecha-
nism [13]. Likewise, Adachi et al in 2000 reported a
patient presenting an androgen insensitivity phenotype,
with normal AR gene; but lacking a protein that interacts
with the AF-1 region of this receptor [14]. Furthermore, it
has been suggested that dysfunction of one member of the
large family of nuclear receptor co-regulators may pro-
duce mild hormone resistance syndromes, since compen-
satory mechanisms might be activated, a scenario
compatible with isolated hypospadias [12]. The pheno-
type of the mice lacking fkbp52 (52KO), the FKBP52
orthologue, supports this concept.
FKBP52 is a tetratricopeptide repeat protein found in ster-
oid receptor complexes, which directly control the tran-
scriptional activity of such receptors [15-17]. To better
assess the physiological importance of FKBP52, 52KO
mice were generated. Surprisingly, 52KO males developed
penile hypospadias with 100% penetrance [18,19]. Dys-
genesis of anterior prostate and seminal vesicle, infertility
and unilateral undescended testis was found in some
mice. No abnormalities in testicular histology were
observed in 52KO males. Gross defects in other organs
and systems were ruled out. No alterations related to other
steroid receptors were identified. The authors concluded
that the phenotype of male 52KO mice is due to loss of
Fkbp52-enhanced AR function [18,19], affecting its asso-
ciation with Hsp90, an important step in establishing and
maintaining hormone binding ability [12-15].
Based on the 52KO mouse phenotype, mutations in
FKBP4 may cause hypospadias in humans. In this report
we examined the sequence and the expression of the
FKBP4 gene in the skin of boys with different severities of
hypospadias, and controls.
Patients and methods
1. DNA analysis
Patients
Ninety-one boys with non-syndromic hypospadias,
recruited through medical records in Sweden, were ran-
domly selected. Of those, 64 were of Swedish origin; 21 of
Middle-Eastern origin and 6 were from other nationali-
ties. Patients with different degrees of severities of hypos-
padias were included: 30 cases had mild, 34 had moderate
and 21 severe hypospadias; for the remaining patients, the
severity was not possible to determine. The screening
included 59 sporadic and 32 familial cases.
SNPs typing was performed in additional 242 non syn-
dromic hypospadias patients, from the Swedish malfor-
mation registry, and 380 voluntary controls, among the
Karolinska Hospital blood donors.
PCR and Sequencing
Genomic DNA was extracted from blood using a standard
phenol/chloroform protocol. Primers (Table 1) flanking
the exon/intron junctions were designed by the Primer 3
program and used to amplify the ten exons of the FKBP4
gene. PCR reactions were performed with DyNAzyme™
EXT DNA Polymerase (Finnzyme, Espoo, Finland) follow-
ing manufacturer protocols (Table 2). After ExoSap-IT
enzyme (USB Europe GmbH, Staufen, Germany) treat-
ment the PCR fragments were sequenced on both direc-
tion using BigDye®  Terminator v3.1 kit (Applied
Biosystems Warrington, United Kingdom) and analyzed
in ABI Prism 3730 Sequencer. Sequence analysis was pre-
formed with the program SeqScape v2.5 (Applied Biossys-
tems).
Genotyping
Two SNPs in the FKBP4 gene were selected from the pub-
lic databases: 1) the SNP rs1062478 (His > Arg), the only
non-synonymous polymorphism in the gene with known
frequency; and 2) the intronic SNP rs3021522 (C > G),
the only polymorphism that was found by sequencing
among the initially 91 screened patients. Typing was per-
formed using a 5'-nuclease allele discrimination TaqMan
assay with standard protocols (Applied Biosystems). The
patients group was further divided into two sub-groups:
1) patients with Swedish ancestry (188); and 2) patients
with non-Swedish ancestry (145). The samples were ana-Reproductive Biology and Endocrinology 2007, 5:8 http://www.rbej.com/content/5/1/8
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lyzed on an ABI 7900HT. Post analysis was performed
with SDS software (Applied Biossystems) and Statistica
7.0.
2. Immunohistochemestry
Antibodies
Rabbit antibody anti-FKBP52 was provided by David
Smith lab [18]. The secondary anti-rabbit antibody was
obtained commercially (Santa Cruz and Vector).
Tissue preparation
Skin samples obtained during surgery from several hypo-
spadias patients of different ages and severities were ana-
lysed for FKBP52 expression. Several age and ethnically
matched healthy individuals were included as non-hypo-
spadic controls, treated for other conditions. As positive
control for the FKBP52 antibody we used human prostate
[18]. Prostate tissue was obtained from a patient surgically
treated for benign prostatic hyperplasia. The tissues were
fixed for 5 to 7 hours in 4% formalin, washed four times
in PBS four times and kept in 70% EtOH until paraffin
embedding.
Immunohistochemistry
After dewaxing and rehydration, the paraffin sections were
treated for antigen retrieval by heating at 98°C in 0.1 M
Tris pH 9.0 for 20 minutes, after which the slides were
allowed to cool to room temperature. Endogenous perox-
idase activity was blocked by treating sections with 1 M
H2O2 for 15 minutes in dark. To block nonspecific anti-
body binding, sections were preincubated in 10 mg/ml
BSA (Sigma) containing 10% goat nonimmune serum
(Vector) for 40 min. Affinity-purified polyclonal anti-
FKBP52 was applied to the sections at a 1:100 dilution in
10 mg/ml BSA and allowed to incubate at 4°C overnight
in a humid chamber. Control sections were incubated
without primary antibody. The sections were incubated
with the biotinylated secondary goat anti rabbit antibody
(Vector) diluted in buffer containing 1% BSA and 10%
goat serum followed by enzyme conjugate application
(ABC, Vector) and chromogen development (AEC, Vec-
tor). All sections were counterstained with hematoxylin
(Merck) for 15 sec before mounting in Kaisers glycerine
gelatine (Merck). Images of immunostained tissued were
captured using a Zeiss microscope. Background controls
were performed similarly using only the secondary anti-
body.
In order to overcome the difficulties in quantifying immu-
nohistochemestry, very standardized procedures were
used to process the sections and the staining.
Results
Sequence analysis
Sequencing of the 10 exons and intronic/exonic borders,
performed bi-directionally, did not reveal any coding
sequence variant in the initially screened ninety-one
patients. The intronic sequence variation rs3021522
Table 2: PCR conditions. PCR reactions were performed with DynaEXT with standard protocols; exon 6 and 7 were amplified as one 
fragment.
Exons 2, 3, 4, 5, 9, 10 Exon 1 Exons 6–7,8
DNA 25 ng 25 ng 25 ng
10×Buffer w.MgCl2 2,5 µl 2,5 µl 2,5 µl
10 mM dNTPs 0,5 µl1   µl 0,5 µl
10 µM forward primer 1 µl1   µl1   µl
10 µM reverse primer 1 µl1   µl1   µl
DyNAzyme™ EXT 0,5 U 1 U 0,75 U
DMSO 0 1 µl0
H2OT o  2 5  µlT o  2 5  µlT o  2 5  µl
Table 1: Primers used for PCR and sequencing.
Forward Reverse
Exon1: GCAGAGGTGCTCAAGCCTC CCTCGGTGCCTTAAACGAC
Exon2: TCCCTTTATGTTCCCTCTGG AACCATTCCTCCCTGAGCTT
Exon3: TTCAGGAGCACTGTTTGAGC GTCTCCAAGAAGCAGGAAGG
Exon4: CTCTCGGATGAGAAAGATTGTG GAGAACGGAAGTGTCTTGCC
Exon5: GCTGATGGCATCCTTCCTC CAAACAGCTGGTTCTACAATTCA
Exon6–7: AGGAAATGGACAGGAAGCCT TCTCAGTCACCAAGGGAAGG
Exon8: AACCTCTTGTGGCCATGTGT CAGACATGCTGGCAGCTCA
Exon9: GGGTACCTTTGGAACCCAGT ACAAAGAGCCCACAGTAGCC
Exon10: CACCAGGCTTGGCCTATACA GCCACCATCCAACCAGATAGReproductive Biology and Endocrinology 2007, 5:8 http://www.rbej.com/content/5/1/8
Page 4 of 7
(page number not for citation purposes)
(915C > G), in intron 6, was found in heterozygous form
in five boys with hypospadias (2 Swedish and 3 Middle
Easters). Analysis of this SNP and of an additional SNP
rs1062478, His > Arg, in exon 4, was performed and ana-
lysed in 333 (including the initial 91) non-syndromic
hypospadias patients and 380 controls. Genotyping
yielded a 95% success rate. Allele and genotype frequen-
cies are presented in table 3; totals represent only success-
ful and unambiguous genotyping results. Differences in
allele and genotype frequencies between patients and con-
trols are not significant using Chi square and Fisher Exact
tests, both when analysing all the patients and when only
individuals with Swedish ancestry are included.
Immunohistochemistry
FKBP52 expression in human tissues
To relate the mouse model more closely with potential
human requirements for FKBP52, we looked at FKBP52
expression in human penile skin from hypospadias
patients. Similarly to the mice, FKBP52 shows expression
in luminal epithelial cells of human prostate (Fig. 1).
FKBP52 immuno-staining is observed in the epidermis of
prepubertal male genital foreskin, containing various cell
types such as keratinocytes and melanocytes. Some stain-
ing is also seen in cells in the dermis, mostly consisting of
fibroblasts and smaller blood vessels (Fig. 2). Though very
similar expression pattern in various hypospadias sec-
tions, unspecific labeling from the primary polyclonal
antibody cannot be absolutely ruled out. Similar to the
prostate where FKBP52 and AR are co-expressed in lumi-
nal epithelial cells, AR is also observed in the epidermal
region of the foreskin, mostly localized to nuclei whereas
FKBP52 staining is predominantly cytoplasmic (not
shown). We could not observe any apparent differences in
the level of FKBP52 staining between mild or severe hyp-
ospadias patients. Besides, the healthy control individuals
show similar pattern and intensity of FKBP52 expression
in the epidermal and dermal regions.
Discussion
Hypospadias is a common birth defect of the male genita-
lia for which the causes are still elusive. Currently, hypos-
padias is repaired surgically, constituting one of the most
common surgeries performed on neonates. Although sur-
gery may remain the therapy of choice, a better knowledge
of the hormonal and molecular mechanisms of genito-
urinary development may be the basis for preventive strat-
egies reducing the incidence of this common malforma-
tion, and even therapeutic approaches.
Androgens have a clear role in the development of the
male reproductive tract, acting via androgen receptor
(AR). The complexity of the nuclear receptor regulation,
including specific and unspecific co-regulators, opens a
highly unexplored area of research in hypospadias; and
has become an obvious target for genetic studies in indi-
viduals presenting signs of undervirilisation [12-14]. Such
could be the case of FKBP52.
Our results evidences that FKBP52, a co-regulator of AR,
which plays a critical role in murine male external genital
development, is expressed in genital skin of prepubertal
boys. However, no obvious difference in the FKBP52
expression was apparent between hypospadias patients
and healthy controls. Furthermore, the sequence analysis
of the FKBP4 gene did not reveal any coding sequence var-
iant. Despite the high homology (89%) between human
and mice FKBP52 proteins, with conserved functional
domains (Fig. 3), our results suggest that alterations on
Table 3: SNP analysis: SNP typing performed in non-syndromic hypospadias patients and in a control population. The differences 
between cases and controls are not significant (p > 0,05). The frequencies on the whole group of patients does not differ from the 
frequencies on the Swedish sub-group (p > 0,05).
rs1062478 His > Arg rs3021522 C > G
PATIENTS CONTROLS PATIENTS CONTROLS
GENOTYPES g/g 0 g/g 1 g/g 0 g/g 0
g/a 1 g/a 0 c/g 16 c/g 24
a/a 327 a/a 378 c/c 317 c/c 351
TOTAL 328 TOTAL 379 TOTAL 333 TOTAL 375
g (All patients) 1 (0.15%) g 2 (0.26%) g (All patients) 16 (2%) g 24 (3%)
ALLELES g (Swedish only) 1 (0.27%) g (Swedish only) 8 (2,2%)
a (All patients) 655 a 756 c (All patients) 650 c 726
a (Swedish only) 367 c (Swedish only) 366
TOTAL (Swedish only) 656 (368) TOTAL 758 TOTAL (Swedish only) 666 (374) TOTAL 750Reproductive Biology and Endocrinology 2007, 5:8 http://www.rbej.com/content/5/1/8
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FKBP52 expression in human prostate Figure 1
FKBP52 expression in human prostate. Prostate tissue was obtained from adult male surgically treated for benign pros-
tatic hyperplasia. The tissue was fixed, paraffin embedded and sectioned before staining. Sections were immunostained with 
antibody specific for FKBP52 (A) and a consecutive section was immunostained with only secondary antibody for background 
detection (B). The strongest staining for FKBP52 is in the cytoplasm of ductal epithelial cells. (Sections photographed at 20× 
magnification).
FKBP52 expression in human pre-pubertal genital skin Figure 2
FKBP52 expression in human pre-pubertal genital skin. Foreskin samples from hypospadia patients and control individ-
uals were obtained from surgery. The tissues were fixed, paraffinembedded and sectioned before staining protocols. The upper 
panel shows FKBP52 staining in mild hypospadia patient (A), severe hypospadia patient (C) and healthy control (E). The back-
ground controls for these samples using only the secondary antibody are seen in (B, D and F). The FKBP52 expression is pre-
dominantly cytoplasmic, localized in the epidermal region of the foreskin. Similar pattern and intensity are observed in healthy 
individuals and in hypospadia patients. (Sections photographed at 20× magnification).
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the human FKBP4 coding sequence and expression are
not a common cause for non-syndromic hypospadias.
These results may indicate that FKBP52 is less important
for full virilisation of the male external genitalia in
humans than in mice.
The amplification of the androgen activity is required for
proper male external genital development in both human
and mice. However differences in the regulation of the
androgen pathway in the two species have already been
described. It has been observed that the disruption of the
5-α reductase 2 gene (Srd5a) in mice does not induce any
abnormal reproductive phenotype, while in humans, the
presence of less active gene variants in its orthologue,
SRD5A2, has been associated to hypospadias [9], infertil-
ity [20] and to various degrees of androgen insensitivity
[21]. It is plausible that the androgen action is increased
in men mainly by the conversion of testosterone to DHT
by SRD5A2, while the mice external genital development
may be more dependent on the combination of AR co-reg-
ulators such as FKBP52.
Indeed, the fine regulation of gene expression and hormo-
nal activity are less well conserved between species then
hormones and hormonal receptors [22]. Another possi-
bility is that mutations in FKBP4 in humans result in other
undermasculinisation phenotypes, which have not been
the target of our study.
Conclusion
The present report indicates that alterations in the
sequence and in the expression of the FKBP4 gene are not
a common cause of non-syndromic hypospadias. Further-
more it alerts to the importance of performing extrapola-
tion from an animal model to humans with caution,
despite the undeniable usefulness of model organisms,
Homology between the FKBP52 protein in humans (ref|NP_002005.1|) and the fkbp52 in mice (ref|NP_034349.1|) Figure 3
Homology between the FKBP52 protein in humans (ref|NP_002005.1|) and the fkbp52 in mice 
(ref|NP_034349.1|). Alignments were performed with ClustalW revealing 89% homology between the two sequences.
HUMAN MTAEEMKATESGAQSAPLPMEGVDISPKQDEGVLKVIKREGTGTEMPMIGDRVFVHYTGW 60 
MURINE MTAEEMKAAENGAQSAPLPLEGVDISPKQDEGVLKVIKREGTGTETPMIGDRVFVHYTGW 60 
********:*.********:************************* **************
HUMAN LLDGTKFDSSLDRKDKFSFDLGKGEVIKAWDIAIATMKVGEVCHITCKPEYAYGSAGSPP 120 
MURINE LLDGTKFDSSLDRKDKFSFDLGKGEVIKAWDIAVATMKVGEVCHITCKPEYAYGAAGSPP 120 
*********************************:********************:*****
HUMAN KIPPNATLVFEVELFEFKGEDLTEEEDGGIIRRIQTRGEGYAKPNEGAIVEVALEGYYKD 180 
MURINE KIPPNATLVFEVELFEFKGEDLTEEEDGGIIRRIRTRGEGYARPNDGAMVEVALEGYHKD 180 
**********************************:*******:**:**:********:**
HUMAN KLFDQRELRFEIGEGENLDLPYGLERAIQRMEKGEHSIVYLKPSYAFGSVGKEKFQIPPN 240 
MURINE RLFDQRELCFEVGEGESLDLPCGLEEAIQRMEKGEHSIVYLKPSYAFGSVGKERFQIPPH 240 
                :******* **:****.**** ***.***************************:*****:
HUMAN AELKYELHLKSFEKAKESWEMNSEEKLEQSTIVKERGTVYFKEGKYKQALLQYKKIVSWL 300 
MURINE AELRYEVRLKSFEKAKESWEMSSAEKLEQSNIVKERGTAYFKEGKYKQALLQYKKIVSWL 300 
***:**::*************.* ******.*******.*********************
HUMAN EYESSFSNEEAQKAQALRLASHLNLAMCHLKLQAFSAAIESCNKALELDSNNEKGLFRRG 360 
MURINE EYESSFSGEEMQKVHALRLASHLNLAMCHLKLQAFSAAIESCNKALELDSNNEKGLFRRG 360 
*******.** **.:*********************************************
HUMAN EAHLAVNDFELARADFQKVLQLYPNNKAAKTQLAVCQQRIRRQLAREKKLYANMFERLAE 420 
MURINE EAHLAVNDFDLARADFQKVLQLYPSNKAAKTQLAVCQQRTRRQLAREKKLYANMFERLAE 420 
*********:**************.************** ********************
HUMAN EENKAKAEASSGDHPTDTEMKEEQKSNTAGSQSQVETEA 459 
MURINE EEHKVKAEVAAGDHPTDAEMKGE-RNNVAENQSRVETEA 458 
**:*.***.::******:*** * :.*.* .**:*****Publish with BioMed Central    and   every 
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especially when it concerns the fine regulation of hormo-
nal signalling, which may be species specific.
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